Wuhan Makes Debut on the List of 'China's Happiest Cities 2021'
January 03, 2022 12:18 ET | Oriental Outlook Weekly Magazine
WUHAN, China, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Wuhan, capital of central China's Hubei Province, has made its debut as one of China's happiest cities in 2021, together with some other provincial...
A statement from AK Consulting and Trans on The COVID-19 Lab Leak - Hypothesis: A Reasonable Suspicion or Conspiracy Theory?
September 10, 2021 07:14 ET | AK Consulting and Trans
STUTTGART, Germany, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Arguments over the idea that the novel coronavirus emerged from a laboratory have escalated for a long time. Most scientists believe that...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program
August 09, 2021 14:39 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat...
COVID-19 Drug Candidate Brilacidin Achieves a Selectivity Index Among the Highest Reported, Exhibiting Potent Anti-SARS-CoV-2 Activity at Low Concentrations; Clinical Trial Forthcoming
August 24, 2020 08:00 ET | Innovation Pharmaceuticals Inc.
Preliminary data shows Brilacidin’s Selectivity Index (SI), a ratio that compares a drug’s cytotoxicity and antiviral activity, to be greater than 300 in a human lung epithelial cell lineBrilacidin’s...
Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line
May 26, 2020 08:00 ET | Innovation Pharmaceuticals Inc.
Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method...
R360 Logo.jpg
Resilience360 and Riskpulse Release Report on Supply Chain Impacts of 2020 Hurricane and Tropical Storm Season
May 19, 2020 09:06 ET | Resilience360
-- Report outlines how hurricane season could compound supply chain vulnerabilities exposed by Covid-19 -- SAN MARCOS, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Resilience360 and Riskpulse have...
Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4
April 27, 2020 09:30 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has been...
Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19
April 01, 2020 08:21 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today it has received data...
Innovation Pharmaceuticals Brilacidin to be Researched as Possible Novel Coronavirus (COVID-19) Vaccine; Brilacidin Now Being Tested as Drug and Vaccine at Different Institutions
March 17, 2020 07:30 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today further details on the...
U.S. Regional Biocontainment Lab to Begin Testing of Brilacidin Against Coronavirus (COVID-19) Next Week
March 10, 2020 08:20 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that...